NCT06332079 2026-01-05
HAITI
Gruppo Oncologico del Nord-Ovest
Phase 2 Terminated
Clinical Trials
64 trialsNCT06046482 2025-10-22
Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT05061420 2025-09-22
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)
Sanofi
Phase 2 Terminated
NCT00766142 2025-08-29
COCHISE
Institut Bergonié
Phase 2 Terminated
NCT05619172 2025-07-24
A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer
Sotio Biotech Inc.
Phase 2 Terminated
NCT04853043 2025-05-06
APK Mutant
University of Utah
Phase 2 Terminated
NCT00551759 2023-07-03
Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer
Eastern Cooperative Oncology Group
Phase 2 Terminated
NCT04106362 2023-06-01
Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With HPV Positive, KRAS-Variant Stage III-IV Oropharyngeal Squamous Cell Carcinoma
Jonsson Comprehensive Cancer Center
Phase 2 Terminated
NCT03254927 2023-04-03
A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma
Celldex Therapeutics
Phase 2 Terminated
NCT04515394 2022-12-22
Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)
EMD Serono
Phase 2 Terminated
NCT03524820 2022-08-04
Cetuximab Therapy for Third Line Rechallenge in Metastatic Colorectal Cancer
Hadassah Medical Organization
Phase 2 Terminated
NCT00321100 2022-01-12
Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab
Fox Chase Cancer Center
Phase 2 Terminated
NCT00904345 2021-02-24
Study of Radiation (RT) Concurrent With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (SCC)
University of Michigan Rogel Cancer Center
Phase 2 Terminated
NCT03887442 2021-01-07
EXTAX
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Phase 2 Terminated
NCT01326923 2020-10-09
Induction Chemo Then Concurrent Chemoradiotherapy With Cetuximab in Locally Advanced Head and Neck Squamous Cell Cancer
Louisiana State University Health Sciences Center Shreveport
Phase 2 Terminated
NCT01133678 2020-05-08
Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck
University of Chicago
Phase 2 Terminated
NCT01609231 2020-05-04
MK-0646-025
Merck Sharp & Dohme LLC
Phase 2 Terminated
NCT00353457 2020-04-09
Capecitabine,Oxaliplatin & Erbitux Given Throughout Multi-Modal Therapy for Locally Advanced Rectal Adenocarcinoma
Abramson Cancer Center at Penn Medicine
Phase 2 Terminated
NCT00541112 2020-02-11
Radiation Therapy, Chemotherapy, and Cetuximab Followed by Surgery, Chemotherapy, and Cetuximab in Treating Patients With Locally Advanced or Metastatic Rectal Cancer That Can Be Removed by Surgery
UNICANCER
Phase 2 Terminated
NCT00955240 2020-02-11
Radiation Therapy, Cisplatin, Fluorouracil, and Cetuximab in Treating Patients With Locally Advanced Anal Cancer
UNICANCER
Phase 2 Terminated
NCT00580073 2019-12-13
Phase II Trial of Neoadjuvant FOLFOX4 and Cetuximab for Localized Adenocarcinoma of Rectum
University of Wisconsin, Madison
Phase 2 Terminated
NCT01230476 2019-10-07
Induction and Concurrent Chemoradiotherapy With Cetuximab for Patients With Locally Advanced Nasopharyngeal Carcinoma
University of Malaya
Phase 2 Terminated
NCT02736578 2019-06-25
Cetuximab-IRDye 800CW and Intraoperative Imaging in Finding Pancreatic Cancer in Patients Undergoing Surgery
Stanford University
Phase 2 Terminated
NCT00611858 2019-01-08
Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT01925274 2019-01-08
A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer
Pfizer
Phase 2 Terminated
NCT02633800 2019-01-07
Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )
Daiichi Sankyo
Phase 2 Terminated
NCT00276744 2018-10-24
Individualized Drug Treatment for Treating Patients With Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT00646659 2018-07-09
Cetuximab, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer That Cannot Be Removed By Surgery
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Terminated
NCT00845039 2018-07-02
FC-4
Eli Lilly and Company
Phase 2 Terminated
NCT00827671 2018-03-09
TRACC
UMC Utrecht
Phase 2 Terminated
NCT01216020 2018-01-17
CTXMAB+RT
Azienda USL 4 Prato
Phase 2 Terminated
NCT00319839 2018-01-12
Study of Albumin Bound-Paclitaxel for Treatment of Recurrent or Metastatic Head and Neck Cancer With Cetuximab
University of California, Irvine
Phase 2 Terminated
NCT01488318 2018-01-05
Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma
University of Pittsburgh
Phase 2 Terminated
NCT01221753 2017-12-06
Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT02316496 2017-08-01
REGAIN
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Terminated
NCT00591149 2017-06-14
Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer
University of Kansas Medical Center
Phase 2 Terminated
NCT00519831 2017-06-09
Ph II of Vinflunine and Cetuximab in Second Line Treatment of NSCLC
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
NCT01794845 2017-05-11
Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma
University of Miami
Phase 2 Terminated
NCT01718808 2017-01-24
Cetuximab for Elderly Patients With mCRC
Swiss Cancer Institute
Phase 2 Terminated
NCT00537823 2016-12-20
Pre- and Post-operative FOLFOX Based Therapy for Patients With Colorectal Cancer With Liver Involvement
Washington University School of Medicine
Phase 2 Terminated
NCT01060423 2016-10-26
DEBIRITUX
Martin-Luther-Universität Halle-Wittenberg
Phase 2 Terminated
NCT01050426 2016-10-14
PERU
Royal Marsden NHS Foundation Trust
Phase 2 Terminated
NCT01522612 2016-06-10
Colorectal Cancer (CRC) Cetuximab Elderly Frail
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Terminated
NCT01858662 2016-04-15
Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 2 Terminated
NCT00448097 2016-03-17
Efficacy and Safety Study of Cetuximab or Cetuximab Plus Docetaxel to Treat Prostate Cancer Before Prostatectomy
The Methodist Hospital Research Institute
Phase 2 Terminated
NCT00271011 2015-12-03
A Study of Mitomycin C, Irinotecan, and Cetuximab
University of Michigan Rogel Cancer Center
Phase 2 Terminated
NCT00599131 2015-12-03
Cetuximab and Radiation Therapy in Laryngeal Cancer Patients Who Have Responded to One Cycle of Chemotherapy (SPORE)
University of Michigan Rogel Cancer Center
Phase 2 Terminated
NCT00109850 2015-11-18
S0414 Cetuximab, Combo Chemo, and RT in Locally Advanced Esophageal Cancer
SWOG Cancer Research Network
Phase 2 Terminated
NCT01004159 2015-10-19
Cetuximab Plus Irinotecan in Colorectal Cancer Patients Who Progressed After Failure With Cetuximab Plus Irinotecan
Roswell Park Cancer Institute
Phase 2 Terminated
NCT00755118 2015-10-07
Lohp, 5-Fu/Lv and Bevacizumab, Alternative With Cpt-11, 5-Fu/Lv and Cetuximab In Metastatic Crc
University Hospital of Crete
Phase 2 Terminated